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Abstract
Verrucosidin (VCD) belongs to a group of fungal metabolites that were identified in screening programs to detect molecules
that preferentially kill cancer cells under glucose-deprived conditions. Its mode of action was proposed to involve inhibition
of increased GRP78 (glucose regulated protein 78) expression during hypoglycemia. Because GRP78 plays an important role
in tumorigenesis, inhibitors such as VCD might harbor cancer therapeutic potential. We therefore sought to characterize
VCD’s anticancer activity in vitro. Triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 were treated with
VCD under different conditions known to trigger increased expression of GRP78, and a variety of cellular processes were
analyzed. We show that VCD was highly cytotoxic only under hypoglycemic conditions, but not in the presence of normal
glucose levels, and VCD blocked GRP78 expression only when glycolysis was impaired (due to hypoglycemia or the
presence of the glycolysis inhibitor 2-deoxyglucose), but not when GRP78 was induced by other means (hypoxia,
thapsigargin, tunicamycin). However, VCD’s strictly hypoglycemia-specific toxicity was not due to the inhibition of GRP78.
Rather, VCD blocked mitochondrial energy production via inhibition of complex I of the electron transport chain. As a result,
cellular ATP levels were quickly depleted under hypoglycemic conditions, and common cellular functions, including general
protein synthesis, deteriorated and resulted in cell death. Altogether, our study identifies mitochondria as the primary target
of VCD. The possibility that other purported GRP78 inhibitors (arctigenin, biguanides, deoxyverrucosidin, efrapeptin, JBIR,
piericidin, prunustatin, pyrvinium, rottlerin, valinomycin, versipelostatin) might act in a similar GRP78-independent fashion
will be discussed.
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Introduction
Verrucosidin (VCD) is a pyrone-type polyketide that is
produced by several species of the genus Penicillium [1,2]. It
belongs to a group of tremorgenic mycotoxins that are known to
act on the central nervous system, thereby causing tremors and
convulsions with an intensity ranging from fully reversible without
notable lesions to entirely fatal [3,4]. Molds producing such
tremorgens pose a recognized health risk to humans and animals
when these microorganisms are present in spoiled food or feed.
For example, livestock grazing on moldy pastures may develop
sporadic locomotor incoordination, where they may stagger, fall
over, and suffer muscular spasms [5,6]. However, the mode of
action for many of these mycotoxins has not been elucidated in
detail.
It was reported recently [7] that VCD was able to kill human
HT29 colon carcinoma cells in culture under glucose-deprived
conditions. As well, VCD blocked the increased expression of
glucose regulated protein 78 (GRP78) [7], a protein that is strongly
induced during hypoglycemic stress and serves to ensure continued
cellular survival under these conditions [8]. GRP78 is a key
component of the unfolded protein response (UPR), a cellular
process that is triggered in response to a variety of stress conditions
that interfere with proper protein folding and processing in the
endoplasmic reticulum (ER) [9]. For example, ER stress and
subsequent activation of the UPR can be caused not only by
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hypoglycemia, but also by hypoxia and intracellular redox
imbalance, as well as by a number of natural compounds, such
as the sequiterpene lactone thapsigargin (which disturbes the
intracellular calcium balance [10]) and the nucleoside antibiotic
tunicamycin (which interferes with glycoprotein synthesis [11]). A
common feature of these ER stressors is the ensuing accumulation
of unfolded and misfolded proteins, and the risk of proteotoxicity.
As an adaptive response, the UPR activates a set of pathways that
result in the transcriptional activation of several important
proteins, including GRP78, aimed at restoring proper protein
processing and overall cellular homeostasis [12,13,14].
The identification of VCD as a GRP downregulator was
through a screening assay based on the activity of a GRP78
promoter-luciferase reporter plasmid, where VCD prevented
increased luciferase expression in response to glucose depletion
or blockage of glycolysis with the hexokinase inhibitor 2-
deoxyglucose (2-DG). A number of other compounds have also
revealed GRP78 transcription inhibitory activity in this screening
assay, such as arctigenin [15], biguanides (metformin, phenformin,
buformin) [16], deoxyverrucosidin [17], efrapeptin J [18], analogs
of JBIR [19], piericidin A [20], prunustatin A [21], pyrvinium
[22], rottlerin [23], valinomycin [24], versipelostatin [25], and
therefore collectively are considered GRP78 downregulators.
The prospect of using these compounds as specific inhibitors of
GRP78 has raised much excitement and extensive interest
[26,27,28,29], because GRP78 is known to play key roles in
cancer cells to ensure their continued proliferation under adverse
conditions, such as hypoglycemia, hypoxia, acidosis, or accumu-
lation of misfolded proteins [30]. Elevated levels of GRP78 are
frequently documented in tumor tissue, where this protein
contributes to cellular survival and resistance against certain types
of chemotherapy [31,32]. In breast cancer in particular, increased
levels of GRP78 have been correlated with treatment resistance
and poor prognosis for affected patients [33,34,35]. Therefore,
GRP78 downregulators may harbor cancer therapeutic potential,
and this aspect is deemed to warrant vigorous investigation [36].
Triple negative breast cancer (TNBC) is a subtype of breast
cancer that lacks estrogen receptor and progesterone receptor
expression, and does not overexpress epidermal growth factor
receptor 2 (Her2/Neu) [37]. Because it carries poor prognosis and
is not amenable to current targeted therapies, TNBC constitutes a
problem with great need and urgency for improved therapies [38].
Like some other cancer types, TNBC cells are able to adapt to
hypoglycemia and indeed continue to thrive under such micro-
environmental conditions, and elevated basal level expression of
GRP78 is among the contributing pro-survival factors under these
otherwise hostile growth conditions [39].
The observation [7] that VCD exerted hypoglycemia-specific
toxicity in colon carcinoma cells, possibly via the inhibition of
GRP78, prompted us to hypothesize that this compound
potentially might exert therapeutic benefit in TNBC. We therefore
performed in vitro studies with representative human TNBC cell
lines (MDA-MB-231 and MDA-MB-468) and characterized their
response to de-novo chemically synthesized VCD. In the process,
we discovered a hitherto unrecognized mechanism by which VCD
accomplishes its cytotoxic outcome, namely by selectively blocking
complex I of the respiratory chain and thus preventing mitochon-
drial ATP production.
Materials and Methods
Pharmacological Agents
Thapsigargin, tunicamycin, 2-deoxyglucose, oligomycin, 2-
thenoyltrifluoroacetone (TTFA), and rotenone were purchased
from Sigma-Aldrich (St. Louis, MO). Verrucosidin was de-novo
chemically synthesized using the route described [40].
Cell Lines and Culture Conditions
MDA-MB-231 and MDA-MB-468 human triple-negative
breast cancer cell lines were obtained from the American Tissue
Culture Collection (ATCC; Manassas, VA). They were propagat-
ed in DMEM (provided by the Cell Culture Core Lab of the
USC/Norris Comprehensive Cancer Center and prepared with
raw materials from Cellgro/MediaTech, Manassas, VA) supple-
mented with 10% fetal bovine serum, 2 mmol/L glutamine,
100 U/mL penicillin, and 0.1 mg/mL streptomycin in a humid-
ified incubator at 37uC and a 5% CO2 atmosphere.
For conventional culture conditions, the medium contained
standard 4.5 g/L glucose (25 mM). For hypoglycemic conditions,
various lower glucose concentrations from 0.0 to 2.5 mM (as
indicated in figure legends) were used. Hypoxic culture conditions
were generated by placing the cells in a GasPak EZ Gas
Generating Pouch System (BD Biosciences, San Jose, CA). In this
system, the amount of oxygen is reduced to 0.7% within 2.5 h, and
decreased further to below 0.1% by 24 h.
MTT Assay
Methylthiazoletetrazolium (MTT) assays were performed as
described earlier [41]. Briefly, cells were seeded into 96-well plates
at 1.0 to 5.06103 cells per well and exposed to drug treatment (or
solvent alone) for 48 or 72 h. In individual experiments, each
treatment condition was set up in quadruplicate, and each
experiment was repeated several times independently.
Colony Formation Assay
Two hundred cells were seeded into each well of a 6-well plate.
After cells had fully attached to the surface of the culture plate,
they were exposed to drug treatment (or solvent alone) for 48 h.
Thereafter, the drug was removed, fresh growth medium was
added, and the cells were kept in culture undisturbed for 12–14
days, during which time the surviving cells spawned a colony of
descendants. Colonies were visualized by staining for 4 h with 1%
methylene blue (in methanol), and then were analyzed and
counted using Image J software.
Immunoblots
Total cell lysates were analyzed by Western blot analysis as
described earlier [42]. The primary antibodies were purchased
from Cell Signaling Technology (Beverly, MA), Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA) or Epitomics (Burlingame,
CA) and used according to the manufacturers’ recommendations.
All immunoblots were repeated at least once to confirm the results.
Determination of Cellular Translation Rate
Cells were grown in 6-cm dishes under standard (25 mM
glucose) or hypoglycemic culture conditions in the presence or
absence of VCD or rotenone for 6 h. Then the monolayers were
rinsed twice with phosphate buffered saline (PBS), and the growth
medium was replaced with methionine-free medium supplement-
ed with 35S-labeled L-methionine to a final activity of 10 mCi per
mL of culture medium. The concentration of glucose and the
respective drug treatment was maintained during this labeling
period. The cells were cultured in the presence of 35S-methionine
for 45 min. Thereafter, cells were harvested in PBS and
transferred to a microcentrifuge tube. After a 30-second spin at
10,000 rpm, the buffer was aspirated and discarded, and the cell
pellet lysed in 100 mL RIPA buffer. Protein concentration of each
Repositioning of GRP78 Inhibitor Verrucosidin
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Figure 1. Cell growth inhibition by VCD. MDA-MB-231 and MBA-MD-468 cells were exposed to VCD treatment in cell culture. (A) Cells were
treated with increasing concentrations of VCD in the absence (0.0 mM) or presence (25 mM) of glucose for 48 h and cell viability was determined by
MTT assay. Removal of glucose by itself (in the absence of VCD) did not substantially interfere with cell viability during this 48-hour period (not
shown). (B) Cells were exposed to VCD in the presence of various concentrations of glucose (as indicated) for 48 h and cell viability was determined
by MTT assay. (C) Cells were exposed to increasing concentrations of VCD in the presence of 25 mM (left panel) or 0.8 mM (right panel) glucose for
48 h; thereafter, VCD was removed and culture conditions were continued in 25 mM glucose for all cells. Long-term cell survival was determined by
counting the number of emerging colonies two weeks later. In all cases, survival of untreated control cells was set at 100%. All values are n$3 (6s.d.).
doi:10.1371/journal.pone.0065695.g001
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sample was determined, and 40 mg of total cell lysate was analyzed
by polyacrylamide gel electrophoresis. After the run, the gel was
stained with Coomassie blue, dried, and exposed to x-ray film.
Cellular Bioenergetics Measurements
Cellular oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) were measured with a Seahorse XF
Extracellular Flux Analyzer (Seahorse Bioscience Inc., North
Billerica, MA) according to the manufacturer’s instructions.
Briefly, thirty thousand cells were seeded per well into a special
96-well plate. After overnight attachment, the medium was
replaced with fresh medium with or without glucose. Basal levels
of OCR and ECAR were recorded for 24 minutes, followed by the
addition of VCD and continuous measurements for another hour.
Intracellular ATP levels were measured by using the ATP
Colorimetric Assay Kit from Biovision (Milpitas, CA) according to
the manufacturer’s instructions. Briefly, 106 cells per 10-cm dish
were exposed to treatment for various time points. Thereafter,
cells were collected and lysed in 100 mL ATP assay buffer. ATP
content in each lysate was determined in a reaction mix that
supported the phosphorylation of added glycerol as a substrate.
The reaction mix was incubated in a 96-well plate at room
temperature for 30 minutes. The OD was measured at 570 nm in
a microplate reader, and ATP content was calculated by applying
sample readings to a standard curve.
Figure 2. Inhibition of GRP78 induction by VCD. GRP78 protein expression was analyzed by Western blot analysis of MDA-MB-231 cells. (A)
Cells were exposed to hypoglycemic (0.8 mM glucose) culture conditions for up to 48 h. Shown are two independent repeats (WB1, WB2) with
different exposure times. (B) Cells were exposed to hypoglycemic culture conditions in the absence or presence of increasing concentrations of VCD
for 24 h. Ctrl: cells were kept in normal (25 mM glucose) culture conditions. (C) Cells were treated with up to 1000 nM VCD under hypoglycemia or in
the presence of 25 mM glucose for 24 h. In all cases, blots were re-probed with an antibody against actin (as a loading control).
doi:10.1371/journal.pone.0065695.g002
Figure 3. Differential inhibition of GRP78 induction by VCD.
Cells were exposed to a variety of known inducers of the ER stress
response in the absence or presence of VCD for 24 hours. 2-
Deoxyglucose was used at 20 mM; thapsigargin and tunicamycin were
used at 200 nM. GRP78 protein expression was analyzed by Western
blot analysis. In all cases, blots were re-probed with an antibody against
actin (as a loading control). Ctrl: untreated cells kept under normal
culture conditions. Ctrl: cells were kept in normal (25 mM glucose)
culture conditions without drug treatment.
doi:10.1371/journal.pone.0065695.g003
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Analysis of Electron Transport Chain Components
The activity of complex I (NADH dehydrogenase) was analyzed
in intact mitochondria that were isolated from mouse liver by
using differential centrifugation as described previously [43]. It was
assayed by monitoring the change in absorbance of the artificial
electron acceptor dichlorophenolindophenol (DCIP) in the pres-
ence of NADH as previously described [44,45] with slight
modifications as follows. Twenty-three microliter of 0.2 M
glycylglycine hydrochloride (pH 8.5), 13 mL of 0.6 mM DCIP,
6 mL of 6 mM NADH (prepared in 0.2 M glycylglycine buffer),
and 48 mL of water were added to each well of a 96-well plate.
Then, 50 mL of the drug to be tested was added. The reaction was
started by the addition of 50 mg of isolated mitochondria to each
well. Complex I activity was monitored by recording the change in
absorbance over time at 600 nm for DCIP against reagent blank.
Figure 4. Combination effect of hypoglycemia and hypoxia. Cells were exposed to hypoglycemia or hypoxia, or both. At different time
points, cells were harvested and Western blot analysis was performed. (A) GRP78 and CHOP expression levels over 24 hours. (B) ATF3 expression
levels during 10 hours of treatment. Actin was used as a loading loading control.
doi:10.1371/journal.pone.0065695.g004
Figure 5. Various protein levels affected by VCD. Cells were cultured in the presence of 0.8 or 25 mM glucose, in the absence or presence of
increasing concentrations of VCD for 24 h. Expression levels of various proteins were analyzed by Western blot analysis. The right panel contains two
different exposures of the GRP78 blot; the short exposure is equivalent to the exposure shown in the left panel, whereas the longer exposure is
included to prominently display the low basal levels of this protein (revealing the absence of an inhibitory effect of VCD). Ctrl: cells were kept in
normal (25 mM glucose) culture conditions.
doi:10.1371/journal.pone.0065695.g005
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The activity of complex II was assayed in intact mitochondria
by following a previously described method [46]. It was monitored
using 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyl tetrazolium
(INT) as the electron acceptor, which forms formazan crystals
on reduction. Briefly, 20 mL of 0.5 M potassium phosphate
(pH 7.4), 20 mL of 1% (w/v in 100% ethanol) INT, 20 mL of
0.5 M sodium succinate, 20 mL of 0.25 M sucrose, and 60 mL of
water were added to each well of a 96-well plate. Then, 50 mL of
the drug to be tested was added. The reaction was started by the
addition of 50 mg of isolated mitochondria. The assay mixture was
incubated at 37uC for 15 min to allow the reaction to proceed.
The reaction was terminated by the addition of 50 mL of 10%
trichloroacetic acid to each well, and the absorbance was read at
490 nm against reagent blank.
The activity of complex V was determined using the MitoTox
Complex V OXPHOS Activity Microplate Assay kit from Abcam
(Cambridge, MA), and manufacturer’s instructions were followed.
Briefly, 50 mL of solubilized bovine heart mitochondria were
added to each well of a pre-coated 96-well plate. The plate was
incubated at room temperature for 2 hours. Thereafter, each well
was washed twice with 300 mL of wash buffer. After washing,
40 mL of phospholipids were added to each well and the plate was
incubated for 45 min at room temperature. At the end of the
incubation period, the drugs to be tested were diluted in complex
V activity solution and 200 mL of the dilution was added in
quadruplicate to the pre-coated 96 well plate. The activity of
complex V was measured by monitoring the change in absorbance
at 340 nm over a period of 1 hour at 30uC.
Statistical Analysis
All parametric data were analyzed using the Student t-test to
calculate the significance values; a probability value (p) ,0.05 was
considered statistically significant.
Results
VCD is Cytotoxic under Hypoglycemic Conditions
Two triple-negative breast cancer cell lines, MDA-MB-231 and
MDA-MB-468, were exposed to increasing concentrations of
VCD in the presence or absence of glucose, and cell survival was
investigated. As determined by MTT assay, VCD was highly
cytotoxic in the absence of glucose, with an IC50 of about 120 nM
in both cell lines (Fig. 1A). In stark contrast, VCD concentrations
of up to 100,000 nM were only weakly effective and killed less
than 50% of the cells under normal (25 mM glucose) culture
conditions. Complete absence of glucose was not necessary for
VCD to unfold its potent cytotoxicity, as this compound very
effectively reduced cellular survival in the presence of 0.25 and
2.5 mM glucose as well (Fig. 1B).
We also determined long-term cellular survival by colony
formation assay. Here, VCD proved even more cytotoxic under
hypoglycemic (0.8 mM glucose) conditions than in the above
short-term MTT assays; 300 nM completely blocked the forma-
tion of any colonies, and the IC50 was well below 100 nM
(Fig. 1C). In comparison, in the presence of 25 mM glucose,
VCD up to 300 nM had no inhibitory effect on colony formation.
Altogether, these results demonstrate a huge differential in VCD’s
cytotoxic potency that is dependent on hypoglycemic conditions.
VCD Blocks GRP78 Induction during Hypoglycemia
GRP78 is a chaperone protein that supports cellular survival
during hypoglycemic conditions. As expected, our hypoglycemic
culture conditions caused strong elevation of GRP78 protein levels
(Fig. 2A). When we exposed cells to hypoglycemia in the presence
of increasing concentrations of VCD, we found that VCD
concentrations as low as 75 nM potently blocked the elevation
of GRP78 protein levels, and the amount of actin protein began to
diminish under these conditions (Fig. 2B) (see Discussion section
for an interpretation of the actin response). Under normal (25 mM
glucose) conditions, VCD effects on GRP78 could not be
observed: because there is no increase in GRP78 levels in the
presence of normal amounts of glucose, it follows that the presence
of VCD, even at a concentration of 1,000 nM, naturally had no
target for blockage (Fig. 2C).
As it is known that GRP78 protein expression is strongly
increased not only in response to lower glucose levels, but more
generally also by a great variety of conditions that cause
endoplasmic reticulum (ER) stress, we next investigated additional
Figure 6. Inhibition of global cellular translation by VCD. Cells
were exposed to 100 nM VCD under hypoglycemic (0.8 mM glucose) or
normal (25 mM glucose) culture conditions. In parallel, hypoglycemic
cells were treated with 100 nM rotenone. After 6 h, the rate of ongoing
protein synthesis was determined. The top panel (autoradiograph)
shows greatly reduced levels of incorporated 35S-labeled amino acids
(indicating severely diminished translational activity) when VCD or
rotenone are present under hypoglycemic conditions. The bottom
panel shows Coomassie blue staining of the same gel to confirm equal
overall amounts of proteins present. Ctrl: cells were kept in normal
(25 mM glucose) culture conditions without drug treatment.
doi:10.1371/journal.pone.0065695.g006
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triggers of ER stress. Cells were exposed to hypoxia, 2-
deoxyglucose (2-DG, an inhibitor of hexokinase), thapsigargin
(an inhibitor of SERCA, i.e., sarcoplasmic/endoplasmic reticulum
calcium ATPase), and tunicamycin (an inhibitor of protein
glycosylation) in the presence or absence of VCD. As shown in
Fig. 3, VCD did not block GRP78 induction in response to
hypoxia, thapsigargin, or tunicamycin; however, it did block
GRP78 induction in response to 2-DG. Thus, altogether VCD
blocked GRP78 induction under conditions that affected glycol-
ysis, namely hypoglycemia and hexokinase inhibition by 2-DG,
but it had no effect on GRP78 induction when other ER stressors
were used.
Hypoxia Displays Effects Similar to VCD
Increased levels of GRP78 represent a reliable marker for ER
stress, but other proteins participate in the ER stress response as
well. Among them is CHOP (CCAAT/enhancer binding protein
homologous protein), which is critical for the pro-apoptotic
function of this cellular program [47]. As well, ATF3 (activating
transcription factor 3) is a general indicator of cellular stress [48].
In order to investigate the mechanism underlying the differential
effects of VCD during hypoglycemia (inhibition of GRP78) vs.
hypoxia (no inhibition of GRP78), we wanted to add VCD to cells
under dual treatment with hypoglycemia plus hypoxia, and then
investigate the stress markers GRP78, CHOP, and ATF3. First,
expression of these three markers was analyzed in the absence of
VCD. To our surprise, and as shown in Fig. 4A, dual treatment
with hypoglycemia plus hypoxia did not result in increased
expression of GRP78 or CHOP, even though individual treatment
with either condition triggered greatly elevated levels of these
proteins. In the case of ATF3, we focused on earlier time points
because stimulation of this general stress marker takes place more
rapidly as compared to GRP78 or CHOP, and greatly elevated
levels were present as early as 2.5 hours (hypoxia) and 7.5 hours
(hypoglycemia) (Fig. 4B). The response of ATF3 to dual
treatment, however, was intriguing: while there was an initial
increase, it was followed by a strong decline, as if the cells ran out
of sufficient energy to mount a further response (Fig. 4B).
The lack of increased GRP78 (and CHOP and ATF3) levels
under dual (hypoglycemia plus hypoxia) treatment condition
precluded the intended addition of VCD to this condition.
However, this outcome was remarkable because it suggested that
hypoxia might mimic the effects of VCD, i.e., hypoxia blocked the
strong increase in GRP78 expression that normally takes place
under hypoglycemic conditions. Because hypoglycemia suppresses
energy production from glycolysis, and hypoxia impedes energy
production from mitochondria, the above result hinted at the
possibility that VCD, rather than acting as a specific inhibitor of
GRP78, might repress energy production from mitochondria.
VCD Inhibits General Cellular Translation
Based on the assumption that VCD might restrict mitochondrial
energy production, its inhibitory effects on GRP78 induction
under hypoglycemic conditions should not be specific, but should
also become evident with other inducible proteins. We therefore
analyzed the expression levels of CHOP and ATF3, which also
represent hypoglycemia-responsive and ER stress-inducible pro-
teins. As shown in Fig. 5, hypoglycemia caused increased
expression of CHOP and ATF3, and this increase was effectively
blocked by 100 nM VCD, similar to what was observed in the case
of GRP78. Basal level expression of a number of other, non-
hypoglycemia-responsive proteins was down-regulated by VCD as
well; among those were cyclin A (a cell cycle regulator), LC3 (a
component of autophagy), PARP1 (involved in DNA repair and
cell survival), and survivin (an anti-apoptotic protein). There was
also a small effect on actin (as noted above in Fig. 2; see
Discussion section for an interpretation of the actin response). In
contrast, under normal (25 mM glucose) culture conditions,
neither cyclin A nor PARP1 nor survivin basal levels were
downregulated by VCD, even at concentrations of up to
1,000 nM. Inhibition of induction of GRP78, CHOP, and
ATF3 cannot be investigated in the presence of 25 mM glucose,
because their expression levels are not stimulated in the presence
of plentiful amounts of glucose. Instead, we investigated the effects
of VCD on basal level (unstimulated) expression of GRP78 by
long-term exposure of the Western blot (to prominently expose the
low levels of GRP78). This revealed that VCD at up to 1,000 nM
Figure 7. Inhibition of ATP synthesis by VCD. Intracellular levels of ATP were determined after incubation of cells under various culture
conditions. Cells were exposed to 100 nM VCD or 100 nM rotenone in the presence of 0.8 or 25 mM glucose for up to 12 h. Ctrl: control for the
respective time point in the absence of drug treatment. Asterisks: p,0.05 (treated compared to untreated cells at the same time point).
doi:10.1371/journal.pone.0065695.g007
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exerted no inhibitory effect on GRP78 in the presence of glucose
(Fig. 5, right panel). Altogether, these results demonstrate that
VCD is able to down-regulate the expression of a number of
genes, not only GRP78, under conditions of low glucose supply;
however, in the presence of plentiful glucose, none of these targets,
inclusive of GRP78, are affected.
Because the above results suggested an inhibitory effect of VCD
on a great number of proteins, not only GRP78, we analyzed total
cellular protein synthesis by measuring overall translational
activity. Cells were treated with VCD, or the respiratory chain
blocker rotenone, in the presence of 25 mM glucose or under
hypoglycemic culture conditions for 6 h; thereafter, translational
activity was determined via the incorporation of 35S-methionine
into newly synthesized proteins. As shown in Fig. 6, VCD did not
noticeably affect incorporation of 35S-methionine in the presence
of normal glucose levels; as well, hypoglycemia by itself did not
reduce 35S-methionine incorporation, which was consistent with
our observation that these tumor cells are fairly resistant to glucose
starvation (not shown). However, VCD did cause a pronounced
(about 80%) decrease in 35S-methionine incorporation under
hypoglycemic conditions, and this inhibitory effect was very
similar in hypoglycemic cells treated with rotenone. Thus, VCD
sharply reduced overall protein synthesis under hypoglycemic
conditions, revealing that VCD inhibited the expression of a very
Figure 8. Metabolic effects of VCD. Cells were exposed to increasing concentrations of VCD in the absence (0.0 mM) or presence (25 mM)
glucose. (A) Mitochondrial respiration was analyzed by measuring the oxygen consumption rate (OCR; pMoles/min). (B) Glycolytic flux was
quantitated by measuring extracellular acidification rate (ECAR; mpH/min).
doi:10.1371/journal.pone.0065695.g008
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large number of proteins, not only GRP78, exclusively under
hypoglycemic conditions. Intriguingly, the mitochondial inhibitor
rotenone appeared to mimic the effects of VCD, further indicating
the possibility that VCD might impinge on cellular energy
production.
VCD Inhibits Mitochondrial Energy Production
To determine VCD’s postulated effects on energy production
more directly, we measured intracellular ATP levels after
treatment of cells with VCD or rotenone in the presence or
absence of glucose. As shown in Fig. 7, neither VCD nor rotenone
displayed pronounced effects on ATP levels when cells were kept
in the presence of normal glucose levels. However, in the absence
Figure 9. Mitochondrial target of VCD. The activities of specific complexes of the electron transport chain were analyzed in intact mitochondria
in the presence and absence of drug treatment. (A) Complex I activity was recorded as absorbance (600 nm) of the electron acceptor DCIP over time.
Note that inhibition of activity by nanomolar concentrations of VCD or rotenone (Rot) resulted in prominently lower absorbance. (B) Complex II
activity was recorded as absorbance (490 nm) of formazan formed after reduction of electron acceptor INT. Note that neither VCD nor rotenone
affected complex II activity (none of the minor variations was statistically significant, i.e., the p-value was greater than 0.05 in all two-sided
comparisons). The known complex II inhibitor TTFA served as the positive control and significantly (p,0.01; asterisks) inhibited complex II activity.
Ctrl: control, i.e., value in the absence of drug treatment. (C) Mitochondrial ATP synthase (complex V) activity was recorded as a decrease in
absorbance (340 nm) over time. Note that ATP synthase inhibitor oligomycin inhibits complex V activity (used as a positive control; right panel), but
neither VCD nor rotenone show inhibitory effect. All assays A-C were repeated at least once and yielded essentially the same outcomes.
doi:10.1371/journal.pone.0065695.g009
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of glucose both compounds drastically lowered intracellular ATP
levels. Hypoglycemia by itself also lowered ATP levels over time
(to 30% at 12 hours), but this decline was substantially slower and
much less severe than in the presence of VCD or rotenone (,5%).
As shown by earlier studies (for examples, see [49,50]), ATP
decline to about 20% can be tolerated by cells for extended
periods (weeks), especially when growth factors/serum are present;
however, if levels drop substantially lower, cellular adaptation
processes (inclusive of autophagy [51]) are unable to compensate
and cells will die (e.g., [52,53]). Therefore, the observed massive
depletion of ATP levels by VCD under hypoglycemic condition is
consistent with general shutdown of cellular functions (inclusive of
global gene expression, Fig. 5) and cell death due to energy
exhaustion.
The bioenergetic effects of VCD were investigated further with
the use of the Seahorse analyzer. This piece of equipment is able to
quantify mitochondrial respiration by measuring the oxygen
consumption rate (OCR); as well, it can quantify glycolytic flux
by measuring the extracellular acidification rate (ECAR). Cells
were exposed to 100 and 300 nM VCD in the presence and
absence of glucose, and OCR and ECAR were measured at 6-
minute intervals for up to one hour. The results are summarized in
Fig. 8 as follows.
VCD dose-dependently decreased OCR in the presence and in
the absence of glucose. While inhibition by 100 nM was fairly
similar under both conditions, 300 nM VCD resulted in greater
OCR inhibition in the absence of glucose. It should be noted,
however, that this latter readout might overestimate VCD’s
inhibitory effect, because in the absence of glucose 300 nM VCD
is much more toxic, which might artificially decrease OCR even
further. Nonetheless, combined these data reveal substantially
impaired mitochondrial respiration in the presence of VCD. On
the other hand, measuring ECAR revealed an up to 50% increase
when VCD was added to glucose-rich medium, whereas addition
of VCD to medium lacking glucose did not result in any ECAR
increase. (In the latter case, 300 nM VCD caused diminished
ECAR, which we suspect might be related to increased toxicity at
this high VCD concentration.) In any case, the ECAR data
indicate that glycolytic flux is greatly increased when mitochon-
drial respiration is impaired by VCD, and, as would be expected,
this outcome only takes place in the presence of glucose.
VCD Inhibits Complex I of the Respiratory Chain
Because of VCD’s impairment of mitochondrial respiration, we
next set out to measure the activity of specific complexes within the
electron transport chain. In particular, we analyzed the effects of
VCD on complex I, complex II, and complex V (ATP synthase).
As summarized in Fig. 9, VCD potently blocked complex I, but
not complex II or complex V. Inhibition of complex I appeared to
be maximal at 100 nM, and further increased concentrations of
VCD (300 and 1,000 nM) exerted only marginally stronger effects.
Intriguingly, blockage of complex I activity by VCD was as
effective as blockage achieved by the classic complex I inhibitor
rotenone, which was used as a positive control (Fig. 9A).
Figure 10. Mimicry of VCD effects by rotenone. Cells were exposed to increasing concentrations of rotenone (Rot) under hypoglycemic
(0.8 mM glucose) conditions or in the presence of 25 mM glucose. (A) After 48 h, cell viability was determined by MTT assay. Survival of cells in the
absence of Rot was set to 100%. (B) Cells were treated with 200 nM tunicamycin (in the presence of 25 mM glucose), were exposed to hypoglycemia
(0.8 mM glucose), or were kept under normal (25 mM glucose) culture conditions, and in all cases 100 or 200 nM Rot was added. After 24 h, cell
lysates were analyzed by Western blot for GRP78 expression. Actin was used as a loading control. Ctrl: cells were kept in normal (25 mM glucose)
culture conditions without any drug treatment.
doi:10.1371/journal.pone.0065695.g010
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Fig. 9B demonstrates that VCD did not impinge on complex II
activity, even at concentrations up to 1,000 nM. Similarly,
rotenone did not affect this complex either, whereas the
established complex II inhibitor TTFA, which was used as a
positive control, led to significant inhibition of this complex. As
well, neither VCD nor rotenone affected the activity of complex V
(Fig. 9C). In contrast, oligomycin, a known inhibitor of complex
V that was used as a positive control, significantly blocked complex
V activity (Fig. 9C). Altogether, these results identify VCD as a
potent inhibitor of complex I of the electron transport chain, with
similar potency as rotenone.
Rotenone Mimics VCD Effects
If the molecular and cellular effects of VCD were primarily
caused by its blockage of complex I activity, one would
hypothesize that the established complex I inhibitor rotenone
should be able to trigger the same outcomes. This possibility
already was suggested by our observation that rotenone inhibited
ATP synthesis and general protein translation under hypoglycemic
conditions very similarly to VCD (Fig. 6 and Fig. 7). We
therefore investigated whether rotenone would be able to mimic
other VCD effects as well. This was indeed the case. As shown in
Fig. 10A, rotenone also exerted hugely differential ability to kill
cells depending on the glucose concentration; while 100 nM was
highly cytotoxic under low-glucose conditions and reduced cell
viability by over 75%, even 100-times higher concentrations were
significantly less toxic in the presence of normal glucose levels.
Rotenone faithfully mimicked VCD’s effects on GRP78
expression as well. It effectively blocked GRP78 induction in
response to hypoglycemia, but had no effect on GRP78 induction
in response to tunicamycin (Fig. 10B). Taken together, the effects
of the electron transport chain blocker rotenone and the effects of
the purported GRP78 downregulator VCD were indistinguishable
in our experiments, in essence qualifying rotenone as a GRP78
downregulator, or conversely VCD as a mitochondrial inhibitor.
The above results indicated that VCD (or rotenone) blocked
GRP78 induction under hypglycemic conditions because com-
bined blockage of the two cellular energy sources (glycolysis and
mitochondria) precluded the availability of sufficient ATP (Fig. 7)
for the synthesis of GRP78 (and many other proteins, Fig. 6). In
comparison, neither VCD nor rotenone blocked GRP78 induction
by tunicamycin (Fig. 3, Fig. 10), presumably because ongoing
glycolysis in the presence of plentiful glucose provided sufficient
energy for protein synthesis to take place. To furnish further
evidence for this conjecture, we pre-treated cells with hypoglyce-
mia+VCD (or hypoglycemia+rotenone) for 8 hours before the
addition of tunicamycin. This pre-treatment, which strongly
reduces cellular ATP levels (Fig. 7), would then be expected to
prevent GRP78 induction by tunicamycin. As shown in Fig. 11,
this was indeed the case. While pre-treatment of cells with VCD
alone or hypoglycemia alone did not interfere with GRP78
induction by tunicamycin, the combination of hypoglyce-
mia+VCD greatly minimized tunicamycin’s ability to stimulate
GRP78 expression (Fig. 11A). As before, rotenone was able to
faithfully mimic VCD’s effect (Fig. 11B).
Discussion
VCD belongs to a group of natural compounds that have
revealed strict hypoglycemia-dependent cytotoxicity and the
ability to block the increased expression of GRP78 that occurs
in response to hypoglycemia. Other members of this group are
arctigenin [15], biguanides (metformin, phenformin, buformin)
[16], deoxyverrucosidin [17], efrapeptin J [18], analogs of JBIR
[19], piericidin A [20], prunustatin A [21], pyrvinium [22],
rottlerin [23], valinomycin [24], and versipelostatin [25]. Because
GRP78 plays an important role in tumorigenesis, such inhibitors
might harbor cancer therapeutic potential. However, based on our
present study with VCD as a representative of this group of
GRP78 inhibitors, the presumed mechanism of antitumor action
of at least some of these compounds should be reconsidered. The
results from our experiments strongly suggest that (i) VCD kills
tumor cells via inhibition of mitochondrial oxidative phosphory-
lation (OXPHOS), and (ii) VCD’s inhibitory effect on GRP78
represents an entirely non-specific consequence secondary to
cytotoxic ATP depletion.
VCD treatment of hypoglycemic cells prevents cellular ATP
synthesis (Figure 7). This combination of hypoglycemia ( = ineffi-
cient ATP synthesis from glycolysis) with VCD (= blockage of
oxidative phosphorylation) leaves no compensatory mechanism for
ATP production, and insufficient amounts of ATP cause
deterioration of critical cellular processes (such as general
translation, Figure 6; and presumably transcription as well). In
the absence of translation, there is no new synthesis of cellular
proteins, which has two consequences: (a) there is no stimulation
(i.e., no increased levels) of hypoglycemia-inducible proteins
(GRP78, CHOP, ATF3, etc.) (Figure 5), and (b) there is a decline
in the levels of highly abundant proteins (cyclin A, LC3, survivin,
PARP1, etc.) over time (Figure 5); we also noted a decline in the
amount of (the very long-lived) actin protein, which becomes more
prominent at longer incubation times (not shown). Thus, VCD
non-specifically blocks the expression of very many proteins, not
just GRP78.
It is important to consider that VCD (and all other purported
GRP78 downregulators of this group) was identified as an
inhibitor of GRP78 transcription (i.e., via the inhibition of a
hypoglycemia-stimulated GRP78 promoter-luciferase reporter
Figure 11. Inhibition of tunicamycin-induced GRP78 expres-
sion by VCD and rotenone. Cells were exposed to hypoglycemia
(0.8 mM glucose) in the presence or absence of 100 nM VCD (A) or
100 nM rotenone (B) at time 0 hours. In all cases, tunicamycin was
added 8 hours later for an additional 16 hours. Thereafter, cell lysates
were prepared and analyzed by Western blot for GRP78 expression
levels. Actin was used as a loading control.
doi:10.1371/journal.pone.0065695.g011
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plasmid), and that this inhibitory effect is specific for hypoglycemia
and does not take place when GRP78 transcription is stimulated
by other types of ER stress. For example, VCD (Figure 3) and
other GRP78 downregulators (arctigenin, efrapeptin J, metformin,
pyrvinium, versipelostatin) block GRP78 transcription during
hypoglycemia (or 2-DG treatment), but not when GRP78 is
stimulated by thapsigargin, tunicamycin, or A23187
[15,16,18,22,25]. This very peculiar differential can be rationally
explained via ATP depletion, which occurs during hypoglycemia
(Figure 7) but not during other types of ER stress that do not
involve impaired glycolysis.
If hypoglycemia-specific cell killing by purported GRP78
downregulators indeed were mediated primarily via mitochondrial
effects, as we claim, one would assume that other means of
mitochondrial impairment would be able to mimic these effects.
This is indeed the case. (i) We found that rotenone, a classic
inhibitor of the electron transport chain (ETC), is hugely more
toxic under hypoglycemic conditions than in the presence of high
glucose levels, and blocks GRP78 induction under hypoglycemia,
but not in response to tunicamycin–just like VCD (Figure 10). (ii)
Hypoxia, which impedes mitochondrial activity, achieves this
outcome as well (Figure 4). (iii) Mitochondrial DNA-deficient (rho-
minus) cells do not tolerate hypoglycemia (or 2-DG) and do not
mount an ER stress response under these conditions, but do
mount a normal response to the ER stressor tunicamycin [54]. (iv)
Others have reported similarly that antimycin A (an ETC
inhibitor) caused tumor cell death and blockage of GRP78
induction under hypoglycemic conditions, but not in combination
with tunicamycin or thapsigargin [54]. (v) As well, rotenone and
antimycin A proved effective in the same screening assay that had
been used to identify VCD and many other GRP78 down-
regulators: both compounds inhibited activation of a GRP78-
luciferase construct under hypoglycemic conditions [54]. Alto-
gether these results provide evidence that a functional respiratory
chain is required for hypoglycemia-stimulated GRP78 expression
and mounting of the ER stress response in general. This view is
fully consistent with textbook knowledge [55] that simultaneous
blockage of glycolysis and OXPHOS results in inevitable depletion
of the cellular ATP pool, and no conveivable cellular defense
mechanism is able to overcome the cytotoxic consequences when
both energy sources remain blocked at the same time. Even
autophagy, the cellular defense mechanism against nutrient
deprivation, ceases to function when ATP levels drop too severely
[51].
It thus emerges that the GRP78-luciferase-based screening assay
that has been used to identify GRP78 downregulators under
hypoglycemic conditions is effective at yielding compounds that
block mitochondrial function. In fact, several of the GRP78
downregulators were known to inhibit mitochondrial ATP
synthesis long before they were identified in this screening assay.
Decades ago, efrapeptin J has been characterized as an inhibitor of
OXPHOS [56], and piericidin A [57] and valinomycin A [58,59]
were shown to block ATP synthesis. Rottlerin has been
characterized as a mitochondrial uncoupler [60]. Prunustatin
and JBIR-type compounds are chemically very similar to the
potent ETC inhibitor antimycin A [18,58]. Arctigenin [61],
pyrvinium [62] and metformin [63,64] have demonstrated ETC
inhibitory activity. Deoxyverrucosidin [17] and the central
compound of our study, VCD, are members of the aurovertin
family of natural compounds and share common structural
features with aurovertin [65,66] and citreoviridin [67,68], which
are highly potent inhibitors of ATPase activity. Thus, most of the
purported GRP78 downregulators display verified or highly
probable impairment of mitochondrial function and ATP synthe-
sis. Conversely, classic OXPHOS inhibitors (rotenone, antimycin
A) were shown to exert GRP78 downregulatory activity when
tested in the GRP78-luc screening assay [54] and, as we
demonstrate, rotenone faithfully mimics each and every effect of
VCD that we have investigated in this present study (Figures 6, 7,
9, 10, 11).
Is it possible that inhibition of GRP78 somehow is involved in
the down-regulation of mitochondrial ATP synthesis, i.e., that
inhibition of OXPHOS is secondary to transcriptional blockage of
GRP78 by these purported GRP78 downregulators? This is not
likely for the following three reasons. (i) In the case of VCD, the
time course of events is reverse. Inhibition of mitochondrial
oxygen consumption (OCR) by VCD takes effect within minutes
(Figure 8), and decreased ATP levels can be detected as early as 2
hours (Figure 7). In comparison, stimulation of GRP78 expression
in response to hypoglycemia is a slow process, where GRP78
protein levels hardly increase within the first 8 hours (Figure 2);
therefore, transcriptional blockage by VCD would not be able to
affect the levels of GRP78 (a long-lived protein) at early time
points where mitochondrial function already is impacted. (ii)
Impairment of mitochondrial function (reduction of OCR) by
VCD also occurs in the presence of plentiful glucose (Figure 8),
where there is no detectable effect of VCD on GRP78. (Reduction
of OCR in the presence of glucose does not lead to substantial loss
of ATP, because of glycolytic compensation, as indicated by
increased ECAR in Figure 8, and the literature, e.g., [58,69]). (iii)
Potent inhibition of complex I of the electron transport chain by
VCD can be verified in isolated mitochondria (Figure 9), i.e.,
under conditions where VCD is entirely unable to impact GRP78
expression.
The repositioning of VCD–and possibly most other members of
the above presented group of GRP78 downregulators–as mito-
chondrial inhibitors would not minimize their therapeutic
potential. In fact, several of the purported GRP78 downregulators,
for example, arctigenin [70], metformin [71,72], pyrvinium [22],
and versipelostatin [25], already have shown anticancer activity
in vivo. As well, based on cancer’s sweet tooth [73], one would
expect that preferential uptake of 2-DG by tumor cells (and
resulting inhibition of glycolysis) should prime malignant cells to
become exquisitely sensitive to killing by such mitochondrial
inhibitors. Indeed, bona fide mitochondrial inhibitors, such as
rotenone, antimycin A, or mito-carboxy proxyl (Mito-CP) have
revealed promising anticancer activity in vivo when combined
with 2-DG [74,75], and this outcome has also been reported when
2-DG was combined with metformin [76]. Altogether, these results
may form the basis for an anti-tumor strategy that hits both
glycolysis and OXPHOS.
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